Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Greenwich Lifesciences Inc GLSI

Healthcare Biotechnology
Greenwich LifeSciences, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of GP2, immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery. GP2 is a 9 amino acid transmembrane peptide of the human epidermal growth factor receptor 2 (HER2)/neu protein, a cell surface receptor protein that is expressed in a... see more

Recent & Breaking News (NDAQ:GLSI)

Greenwich LifeSciences Partners with GIM in Italy

GlobeNewswire 5 days ago

Greenwich LifeSciences Provides Update on Corporate Events

GlobeNewswire 13 days ago

Greenwich LifeSciences Provides Update on Expansion of Flamingo-01 into Spain

GlobeNewswire August 1, 2024

Greenwich LifeSciences Set to Join Russell 2000 Index Again

GlobeNewswire June 26, 2024

Greenwich LifeSciences Announces $2.5 Million Private Placement

GlobeNewswire June 14, 2024

Greenwich LifeSciences Extends Lock-up of Directors and Officers to June 30, 2025

GlobeNewswire March 13, 2024

Greenwich LifeSciences Partners with GEICAM in Spain & Conducts First Site Initiation Visits in Europe

GlobeNewswire March 12, 2024

Greenwich LifeSciences Flamingo-01 Phase III Clinical Trial Approved to Expand into Five Largest European Countries

GlobeNewswire February 27, 2024

Greenwich LifeSciences Flamingo-01 Manufacturing & Protocol Accepted by European Regulators

GlobeNewswire February 22, 2024

Greenwich LifeSciences Provides Update on Phase III Clinical Trial, Flamingo-01

GlobeNewswire February 14, 2024

Greenwich LifeSciences Extends Lock-up of Directors and Officers to End of 2024

GlobeNewswire November 21, 2023

Greenwich LifeSciences Provides Year End Update

Business Wire December 29, 2022

Greenwich LifeSciences Extends Lock-up of Directors and Officers to End of 2023

Business Wire December 1, 2022

Greenwich LifeSciences Announces Activation of Clinical Sites and Commencement of Phase III Clinical Trial

Business Wire August 11, 2022

Greenwich LifeSciences Provides Updates on Flamingo-01 Phase III Clinical Trial

Business Wire August 3, 2022

Greenwich LifeSciences Provides Financing Strategy & Corporate Update

Business Wire July 28, 2022

Greenwich LifeSciences Announces Removal of Clinical Hold Permitting Phase III Clinical Trial to Proceed

Business Wire July 12, 2022

Greenwich LifeSciences Announces Suspension of Share Repurchase Program

Business Wire July 11, 2022

Greenwich LifeSciences to Resume Stock Repurchase Program

Business Wire May 23, 2022

Greenwich LifeSciences Provides Updates on Upcoming Phase III Clinical Trial & ASCO Meeting

Business Wire May 23, 2022